Experts Prof. de Mestier, Prof. Vandamme, and Dr Durand share their insights on the latest data presented at the ENETS 2026 conference and discuss how these may impact clinical practice.

 

Watch the video update to hear the Experts discuss the breakthrough results presented from the COMPETE study with PRRT in pancreatic NETS before targeted therapy, as well as opinions on strategies for re-challenge with PRRT in NET patients.

 

They also discuss the positive data from the DAREONTM-7 trial of obrixtamig, a DLL3-targeted bi-specific T cell engager, as 1st line therapy for advanced NEC, and the role of surgery in stage 1–3 disease. In addition, they discuss the interesting combination treatment of cabozantinib and temozolomide for NETs.

 

 

Clinical takeaways

  • A COMPETE trial subgroup analysis demonstrated significant benefit of PRRT over everolimus, supporting integration of PRRT before targeted therapy in the treatment sequence
  • Re-challenging PRRT in NET patients showed promising efficacy, although there is a need for careful hematological monitoring
  • Obrixtamig, a DLL3 bi-specific T cell engager, achieved disease control as 1st line therapy for advanced NECs with durable responses, suggesting an encouraging new therapeutic approach
  • Surgical resection of stage 1−3 NECs is associated with improved survival compared to chemotherapy; most relapses occur within 3 years with no relapses after 4.5 years, informing follow-up duration post-resection
  • Evaluate the latest scientific data presented at ENETS 2026 and understand the clinical implications
  • Identify the latest practice-changing evidence

Prof. Louis de Mestier, MD, PhD, is Full Professor of Gastroenterology at Université Paris-Cité, and serves as a Senior Consultant in the Department of Pancreatology and Digestive Oncology in Beaujon Hospital (APHP, Clichy, France). His main area of clinical expertise, research and teaching is digestive neuroendocrine neoplasms. He conducts clinical and translational research on the clinical and biological heterogeneity of neuroendocrine neoplasms and its therapeutic applications at the INSERM U1149 Research Unit in Paris. He has contributed to more than 170 medical publications, including more than 100 indexed papers in the field of neuroendocrine neoplasms. He is a member of the Advisory Boards of ENETS and GTE.

Prof. Louis de Mestier has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astellas, BMS, Boehringer-Ingelheim, Esteve, Ipsen, Novartis, Mayoly, Servier & Viatris.

Timon Vandamme is a Senior Consultant in digestive and neuroendocrine oncology at the Antwerp University Hospital. As a clinician-researcher, he is performing research in circulating cell-free DNA (ccfDNA) in digestive and neuroendocrine neoplasms.

 

Dr Vandamme obtained a joint PhD at the University of Antwerp, Belgium and the Erasmus MC, the Netherlands, on preclinical and translation evaluation of everolimus resistance and pancreatic NET genomics. His PhD project has led to multiple publications in peer-reviewed journals and received numerous awards, both national and international. Currently, he is holder of a Senior Clinical Investigator (FKM) grant of the Fonds Wetenschappelijk Onderzoek (FWO) at the University of Antwerp.

 

Furthermore, he is the Principal Investigator (PI) of > 10 trials at the University Hospital Antwerp, both industry-sponsored and academic trials. He is promotor of four PhD students and mentor of two additional PhD students. He has authored numerous papers outside his PhD in journals such as Clinical Cancer Research and Lancet Oncology. He has peer-reviewed for different high-impact journals and is a member of the editorial board of Endocrine-Related Cancer.

He is currently acting secretary of the Dutch Belgian Neuroendocrine Tumor Society (DBNETS) and co-opted board member of the Belgian Group of Digestive Oncology (BGDO). In addition, he is active member of the EORTC GI Tract Cancer Group and the ENETS Translational Working Group.

 

Prof. Timon Vandamme has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Astellas, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Incyte, Ipsen, MyNeoTx, MSD, Nordic Pharma, Novartis, Roche, Sirtex, Servier & Takeda.

Medical oncologist at the Hospices Civils de Lyon (France), specialising in digestive oncology and neuroendocrine tumours, working in the nuclear medicine department as part of the PRRT programme.

 

Areas of research are particularly PRRT lung carcinoids, and issues relating to care pathways for rare tumours.

Dr Alice Durand has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Ipsen and Servier

Programme summary
  • clock Duration 5 MIN
  • clock Language(s) flag flag
Watch the video now
Other episodes of this series
Update from ENETS 2026

Update from ENETS 2026

Experts share their views on latest data in neuroendocrine cancer

Current Episode
Actualités du Congrès l’ENETS 2026

Actualités du Congrès l’ENETS 2026

Points de vue d’experts sur les dernières données concernant le cancer neuroendocrinien

Share this programme
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Ipsen. The content published on this website is under the responsibility of its authors. Some scientific data published on this website may not have been validated by the relevant Marketing Authorisation Committees and should not be put into practice. It should be read and understood with the utmost discernment and is provided for the purpose of disseminating information on the current state of research to the international scientific community.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
NET CONNECT

NET CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Ipsen, Eisai Europe Limited, ITM and Boehringer Ingelheim

Meet the experts Independent IME approved

Other programmes of interest

Infographic / Flashcard
Oncology Rare diseases 
EP-NEC at a glance

Understanding EP-NEC, emerging treatments, and patient care strategies

Experts
Meredith Cummins
  • download Downloadable
    Resources
  • clock 1 MIN
  • calendar May 2026

This programme has been sponsored by Boehringer Ingelheim
eks
EKS / On-demand webinar
Oncology 
The evolving TROP2-directed ADC landscape in metastatic NSCLC

Strategies to optimise the treatment experience

Experts
Prof. Nicolas Girard, Dr Louise Lim, Dr Jacob Sands, Mrs Stephanie McDonald
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 58 MIN
  • calendar May 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca
conference-update Conference update
Oncology 
Highlights from ASCO 2026

Coming soon! Expert insights on the latest data

Experts
Dr Herbert Loong, Dr Isabel Preeshagul, Prof. Mark Socinski, Prof. Evan Yu, Prof. Hans Prenen, Dr Paolo Tarantino
  • clock 5 MIN
  • calendar May 2026
  • Non-accredited Independent Medical Education

expert-video-animation Animated Video
Rare diseases 
Evolving care in narcolepsy type 1

The emergence of orexin-targeted therapies

Experts
Prof. Yves Dauvilliers
Endorsed by
ANC Reference centre
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Apr 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Takeda
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from ELCC 2026

Expert insights on the latest NSCLC data

Experts
Prof. Nicolas Girard
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
ISLB Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Pre-analytical phase challenges and biomarker testing in HER2+ metastatic breast cancer

Experts
Dr Carlos Barrios, Prof. Gary Tse, Oncology Brothers (Moderators)
Endorsed by
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Daiichi Sankyo